Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Cell Stem Cell · 2025-01 · 32 (1) · 10-37
DOI: 10.1016/j.stem.2024.12.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Stem Cell, 2025-01. Verfasst von Agnete Kirkeby und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) and Department of Neuroscience, Faculty of Health and Medical Sciences, University of C…. Hauptthemen laut MEDLINE: Cell- and Tissue-Based Therapy, Clinical Trials as Topic, Pluripotent Stem Cells. Die Arbeit wurde bisher 216-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation.
Abstract (Originalsprache)
Since the first derivation of human pluripotent stem cells (hPSCs) 27 years ago, technologies to control their differentiation and manufacturing have advanced immensely, enabling increasing numbers of clinical trials with hPSC-derived products. Here, we revew the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, we identify 116 clinical trials with regulatory approval, testing 83 hPSC products. The majority of trials are targeting eye, central nervous system, and cancer. To date, more than 1,200 patients have been dosed with hPSC products, accumulating to >1011 clinically administered cells, so far showing no generalizable safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) and Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; Department of Experimental Medica…
- HOYA Consulting (ReGenMed Solutions), Stockholm, Sweden.
- Carpenter Consulting Corporation, Washington, USA. Electronic address: melissa@carpentergroupstrategy.com.
Förderung
- Novo Nordisk Foundation
Zitieren
APA
Kirkeby, A., Main, H., & Carpenter, M. (2025). Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell, 32(1), 10-37. https://doi.org/10.1016/j.stem.2024.12.005
Vancouver
Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell. 2025;32(1):10-37. doi:10.1016/j.stem.2024.12.005
BibTeX
@article{Kirkeby2025,
author = {Kirkeby, Agnete and Main, Heather and Carpenter, Melissa},
title = {Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update},
journal = {Cell Stem Cell},
year = {2025},
volume = {32},
number = {1},
pages = {10--37},
doi = {10.1016/j.stem.2024.12.005}
}
EUVIMED